AJP - GI Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 291: G16-G25, 2006; doi:10.1152/ajpgi.00328.2005
0193-1857/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A corrigendum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in AJP - GI
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scheving, L. A.
Right arrow Articles by Russell, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scheving, L. A.
Right arrow Articles by Russell, W. E.

LIVER AND BILIARY TRACT

The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling

Lawrence A. Scheving,1,3 Linda Zhang,1 Mary C. Stevenson,1 Eun Soo Kwak,1 and William E. Russell1,2,3,4,5

1Division of Endocrinology, Department of Pediatrics, 2Department of Cell and Developmental Biology, 3Digestive Disease Research Center, 4Vanderbilt Diabetes Center, and 5Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee

Submitted 18 July 2005 ; accepted in final form 15 March 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The proliferative effects of EGF in liver have been extensively investigated in cultured hepatocytes. We studied the effects of EGF, insulin, and other growth regulators on the expression, interaction, and signaling of ErbB receptors in primary cultures of adult rat hepatocytes. Using immunological methods and ErbB tyrosine kinase inhibitors, we analyzed the expression and signaling patterns of the ErbB kinases over 120 h of culture. Basal and EGF-stimulated protein tyrosine phosphorylation increased as cells adapted in vitro. EGF receptor (EGFr) expression declined in the first 24 h, whereas ErbB3 expression rose. Although ErbB2 was not present in freshly isolated hepatocytes, EGF and insulin independently induced ErbB2 while suppressing ErbB3 expression. Low concentrations of EGF and insulin synergistically stimulated ErbB2 expression and DNA synthesis. The greatest increase in ErbB2, which is normally expressed by fetal and neonatal hepatocytes, occurred shortly before the onset of DNA synthesis (>40 h). EGF promoted EGFr and ErbB2 coassociation, stimulating tyrosine phosphorylation of both proteins. In contrast, heregulin beta1 (HRG-beta1) did not promote ErbB2 and ErbB3 coassociation. A selective tyrphostin inhibitor of ErbB2 suppressed EGF-stimulated DNA synthesis, but maximum suppression required the blockade of the EGFr kinase as well. Maximal EGF stimulation of DNA synthesis in vitro depends on the induction of ErbB2 and involves an EGFr-ErbB2 heterodimer. The ability of insulin to induce ErbB2 suggests both a mechanism for the synergy between insulin and EGF and a possible metabolic control of ErbB2 in vivo.

hepatocyte; liver; TGF-{alpha}; cell culture

EPITHELIAL GROWTH FACTOR (EGF), transforming growth factor (TGF)-{alpha}, and other ligands of the EGF receptor (EGFr) regulate the growth, regeneration, differentiation, and malignant transformation of the liver. These ligands arise from an 11-member gene family whose multiple splice variants share a common EGF motif that can activate selective members of the ErbB (HER, in human cells) family of transmembrane tyrosine kinase receptors (11). EGFr (ErbB1) is the receptor for EGF, TGF-{alpha}, amphiregulin, betacellulin, and epigen. ErbB3 and ErbB4 are the unique receptors for the heregulin (HRG; or neuregulin) family of EGF-like ligands. HB-EGF and epiregulin are amphipathic ligands that can activate either EGFr or ErbB4 (17). ErbB2 is a potent tyrosine kinase and signal transducer that has no ligand (11). ErbB2 can heterodimerize with ligand-activated ErbB receptors (EGFr, ErbB3, or ErbB4). Alternatively, ErbB2 molecules can homodimerize into ligandless signaling complexes when overexpressed by certain cancer cells. In contrast to other ErbB proteins, ErbB3 has an inactive kinase domain. Although it can bind ligands, it must dimerize with other kinase-active family members such as EGFr or ErbB2 to transduce HRG signals (4). Because each ErbB receptor can activate distinct intracellular signaling cascades, diverse biological response patterns arise from different ErbB associations.

We previously reported that ErbB expression patterns and combinatorial interactions vary during rat liver development (5). Fetal hepatocytes express three of the four ErbB-receptor tyrosine kinases: EGFr, ErbB2, and ErbB3. However, ErbB2 expression ceases at or near weaning. The adult rat hepatocyte, therefore, expresses only EGFr and ErbB3, lacking ErbB2 or ErbB4, even during periods of intense proliferation, such as regeneration following 70% hepatectomy.

Hepatocyte cultures from adult rats are highly useful for the study of factors that regulate cell proliferation, but the hepatocyte in primary culture does not always mirror the hepatocyte from the intact liver. For example, over 80% of cultured hepatocytes can respond to exogenous EGF with increased DNA synthesis. In the intact liver, the DNA synthesis response to EGF is considerably less, unless hepatocytes are primed to respond to EGF in vivo, such as by collagenase pretreatment (14). In this case, the apparent labeling index reaches 50%, which is comparable to that seen after partial hepatectomy. Despite the greater fractional growth response of hepatocytes from adult rats in vitro, their entry into the S phase is slower than in vivo. For example, DNA synthesis begins to rise 44 h after EGF is added to the initial growth medium shortly after cell plating. However, when EGF is injected intraperitoneally, DNA synthesis increases as early as 8–12 h after administration (30, 37). DNA synthesis in the regenerating rat liver also starts to increase 15 h after partial hepatectomy, peaking at 20–24 h. In contrast to adult hepatocytes, cultured fetal or neonatal hepatocytes show a shorter lag phase than adult cells, with peak EGF-stimulated DNA synthesis occurring by 24 h (10).

EGF-stimulated DNA synthesis is strongly amplified by insulin in adult but not fetal hepatocytes (27). In the presence of insulin, low concentrations of EGF (high picomolar to low nanomolar) can stimulate DNA synthesis to the same extent as high concentrations of EGF (10 nM) in the absence of insulin. Also, in the presence of insulin, the adult hepatocyte DNA synthesis response to EGF becomes greater as the time in culture increases. For example, the lag phase before DNA synthesis decreases by 20 h for insulin-treated cells exposed to EGF between 48 and 72 h after plating compared with cells exposed to EGF between 0 and 24 h. Hepatocytes exposed to EGF at later times also synthesize DNA in a more synchronized fashion. The level of peak DNA synthesis in the 48- to 72-h treatment group is four times greater than that of the 0- to 24-h treatment group (15). Thus insulin induces changes in cultured adult hepatocytes that increase their sensitivity to EGF as defined by the threshold dose required to stimulate DNA synthesis as well as by the rapidity and synchronicity of response.

Altered patterns of ErbB-receptor expression could explain some of these unique features of the hepatocyte response to EGF in vitro. We now report that insulin and EGF independently induce ErbB2 expression in adult rat hepatocytes after 24 h of culture. The expression of ErbB2 precedes the G1-S transition and correlates with the induction of cyclin D1 expression. We provide evidence that an EGFr-ErbB2 signaling complex emerges in cultured hepatocytes, which mediates EGF-induced DNA synthesis. This complex requires the kinase activity of both the EGFr and ErbB2. Our data implicate ErbB2 induction as a component of the synergy between EGF and insulin in vitro. Our data also suggest that metabolic factors may control ErbB2 expression in the liver.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Peptides, reagents, and radiochemicals. Human recombinant HRG-beta1 (amino acids 177–244) was from R&D Systems (Minneapolis, MN). Insulin (Novolin R) was from Novo Nordisk (Princeton, NJ), and glucagon was from Eli Lilly (Indianapolis, IN). Synthetic rat TGF-{alpha} was from Peninsula Laboratories (Belmont, CA). [3H]thymidine (6 Ci/mmol) was from Perkin-Elmer (Boston, MA). Dexamethasone, pyruvate, bovine serum albumin (fatty acid-free), Percoll, and all buffer reagents were from Sigma (St. Louis, MO). Protein G-Sepharose and chemiluminescence reagents were from Pierce (Rockford, IL). Nitrocellulose membranes were from Osmonics (Minnetonka, MN). Engelbreth-Holm-Swarm (EHS) extract was from Upstate Biotechnology (Lake Placid, NY).

Culture media and supplies. Williams' medium E, supplemented with 20 mM pyruvate, 10 nM dexamethasone, and 50 µg/ml gentamicin, was the medium used for all culture studies. Medium and calf serum were from GIBCO-Invitrogen (Grand Island, NY). Type I collagenase was from Wako Pure Chemical Industries (Richmond, VA). Falcon six-well dishes were from Fisher. Tyrphostins AG 1478, AG 825, and AG 879 were from Calbiochem (San Diego, CA) and dissolved in DMSO.

Animals. Adult male Sprague-Dawley rats from Harlan (Indianapolis, IN) were housed under conditions of regulated lighting (lights on 0600–1800). They had access to water and Purina rodent chow ad libitum (Ralston-Purina, St. Louis, MO). The Animal Use Subcommittee of the Vanderbilt Animal Care Committee approved all protocols.

Primary cell cultures. We isolated hepatocytes from the livers of male rats between 10:00 and 11:30 AM to control for circadian variation using a two-stage, collagenase isolation protocol (4). Cells were sedimented through Percoll to reduce nonhepatocyte contamination (4). We plated cells (3.75 x 105 cells/well) in type I collagen-coated, 6-well (35-mm) plates for 60–90 min before adding serum-free medium containing hormones, cytokines, or signaling pathway inhibitors. In some experiments, we exposed the hepatocytes to an EHS mouse tumor extract overlay after 24 h in culture as previously described (20).

Immunoprecipitation and Western blot analysis. Hepatocytes were lysed in TGH buffer (20 mM HEPES, 1% Triton X-100, 10% glycerol, and 50 mM NaCl). This buffer included protease inhibitors (10 mM PMSF, 1 mM sodium orthovanadate, 10 µg/ml aprotinin, and 10 µg/ml leupeptin) as well as phosphatase inhibitors (10 mM sodium molybdate and 10 mM beta-glycerol phosphate). Lysates were microcentrifuged at 20,800 g for 30 min and then immunoblotted or immunoprecipitated as previously described (5). The affinity-purified antibodies used were from Santa Cruz Biotechnology (Santa Cruz, CA), sc-03 for EGFr, sc-284 for ErbB2, sc-285 for ErbB3, and sc-283 for ErbB4. The anti-phosphotyrosine antibody used was RC20H (Signal Transduction Laboratories, Lexington, KY) or PY99 (Santa Cruz Biotechnology). The anti-phosphotyrosine (Y1112)-ErbB2 antibody was from Orbigen (San Diego, CA). We normalized all immunoprecipitations or immunoblots by using equal amounts of protein and confirmed equal protein loading and transfer by Ponceau S staining of immunoblots. Immunoreactive signal was detected using the ECL method (Pierce). We performed densitometry using an Epson scanner with Biosoft Quantiscan software.

Nucleic acid probes and Northern blot analysis. For ErbB2, we used as a cDNA probe rat neuc(t)SP6400 clone (420 bp long) inserted into vector pSP65 (American Type Culture Collection, Rockville, MD). A neu fragment was generated by digestion of the plasmid SP6400 with restriction enzyme BamH1 and then gel purified before labeling. The probe was labeled with [{alpha}-32P]dCTP by a random priming method. For EGFr, we used as a cRNA probe the TRI-EGFR-human probe containing human EGFr (350 bp, including nucleotides) inserted into a Triple script vector (Ambion, Austin, TX). The probe was labeled with [{alpha}-32P]dUTP by use of the strip-EZ RNA probe synthesis kit (Ambion).

The Northern blot was carried out as previously described (28). RNA from hepatocytes was isolated by TRI Reagent (Molecular Research Center, Cincinnati, OH) following the manufacturer's instructions. The glyoxal-dimethylsulfoxide-denatured RNA was electrophoresed on a 1% agarose gel (20 µg/lane), transferred to a positively charged nylon membrane (Ambion Northern Max kit), and cross-linked to the membrane using ultraviolet light (Stratalinker; Stratagene, La Jolla, CA). Equal loading was confirmed by visualization of the 28S and 18S subunits. Prehybridization and hybridization were carried out at 42°C for the DNA probe or 68°C for the RNA probe using buffers provided by the kit. After hybridization, the membranes were washed with low- and then high-stringency washing buffers as directed by the manufacturer's instructions. The blots were then exposed to Kodak XAR-5 film at –80°C with double intensifying screens.

DNA synthesis assays. After 48 h in culture, cells were refed with medium containing specified growth factors and 1 µCi/ml of [3H-methyl]thymidine. At 72 h, the experiment was terminated, and the incorporation of tracer was determined as detailed previously (4). The results of assays in triplicate are expressed as the specific activity of the DNA (disintegrations·min–1·µg DNA–1).

Statistical analysis. Statistical analysis was performed using an unpaired, two-tailed Student's t-test assuming equal variances between compared groups.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Hepatocytes show increased protein tyrosine phosphorylation in response to EGF with increasing time in culture. Because cultured hepatocytes display an increased DNA synthesis response when the addition of EGF to medium is delayed until several days after plating (15), we studied how the EGF-stimulated and basal tyrosine phosphorylation patterns varied with time in culture. We cultured cells in the presence or absence of insulin (100 nM) and a submitogenic dose of TGF-{alpha} (0.1 nM). At different times after plating, we then exposed them to EGF (100 nM) or HRG-beta1 (100 nM) for 1 min and assessed tyrosine phosphorylation of lysate proteins by immunoblot analysis. Figure 1A shows that the overall basal and EGF-stimulated levels of phosphorylation increased with time between 48 and 96 h in culture. Figure 1B shows the basal and EGF-stimulated tyrosine phosphorylation signal obtained from each lane of the insulin-treated cells as a function of time. Also, the response of cells to EGF or HRG-beta1 varied. HRG-beta1 strongly stimulated ErbB3 and EGFr phosphorylation at 4 or 24 h but not at later times. Insulin, which suppresses expression of the HRG receptor ErbB3 (4), decreased HRG-beta1-stimulated phosphorylation at 24 h.


Figure 1
View larger version (60K):
[in this window]
[in a new window]
  		Fig. 1. Basal and EGF-stimulated tyrosine phosphorylation increases during long-term hepatocyte culture. A: primary hepatocytes were cultured for the indicated times in the presence of insulin (INS; 100 nM) and then treated with EGF (E, 100 nM) or heregulin-beta1 [HRG-beta1 (H); 100 nM] for 1 min. Lysates prepared from these cells were analyzed for phosphotyrosine content by immunoblotting with an anti-phosphotyrosine antibody. Note the increased basal and EGF-stimulated tyrosine phosphorylation with culture time. B: selected lanes from A (lanes "–" and "E" from insulin-treated cells at 4, 24, 48, 72, and 96 h) were scanned by densitometry, and the total phosphotyrosine signal within each lane was plotted as a function of time. Shown is how the basal and EGF-stimulated tyrosine phosphorylation (PY) increased after 48 h.

 
Temporal changes in ErbB expression in vitro. To study ErbB expression in hepatocytes over 5 days in culture, we prepared lysates of cells cultured in medium alone (referred to as "basal") or in the presence of insulin (100 nM), EGF (6.3 nM), or insulin plus EGF. We quantified ErbB protein expression by densitometric analysis of immunoblots. Figure 2 shows the expression patterns of ErbB1, -2, and -3 over 160 h after cell plating. EGFr declined by over 80% within 24 h of culture in all conditions (Fig. 2, top); however, there was a slight rebound in expression between 48 and 72 h in the cells exposed to insulin or EGF. Others have reported a reduction in EGF binding during the first 24 h of culture, correlating with a loss of high-affinity EGF binding sites (36). Consistent with our previous findings (4), ErbB3 expression increased threefold during the first 24 h of culture, although insulin and EGF suppressed this surge, especially when combined (Fig. 2, middle). Although we detected faint basal ErbB2 expression in hepatocytes cultured in basal media between 72 and 96 h (Fig. 2, bottom), insulin and EGF each induced ErbB2. EGF (6.3 nM) induced ErbB2 to a greater extent than insulin alone or insulin and EGF together. Figure 3A shows the immunoblot images of ErbB2 and ErbB3 expression, highlighting their inverse expression patterns. We could not detect ErbB4 during the 166-h harvest period (data not shown).


Figure 2
View larger version (18K):
[in this window]
[in a new window]
  		Fig. 2. Time course of ErbB protein expression during primary rat hepatocyte culture. ErbB protein levels were determined in primary hepatocytes over a 166-h period and then analyzed by scanning-laser densitometry of immunoblots. The effect of insulin (100 nM) and EGF (6.3 nM), alone or in combination, on ErbB expression was determined. Each data point represents the expression of a Triton X-100-solubilized lysate. The densitometric units are arbitrary and do not reflect the absolute abundance of the respective ErbB proteins.

 

Figure 3
View larger version (41K):
[in this window]
[in a new window]
  		Fig. 3. Temporal expression of ErbB2 and ErbB3 proteins during rat hepatocyte culture. A: data shown were used to generate the ErbB2 and ErbB3 parts of Fig. 2. Time 0 is 90 min after plating, when Williams' medium E (WE) replaced the original plating medium. Each lane included 50 µg of protein and equal transfer for each lane was confirmed before blotting by Ponceau S staining. B: EGFr and ErbB2 Northern blot showing the induction of ErbB2 in cultured cells. Each lane was loaded with 20 µg of total RNA taken from plates harvested in parallel at the designated times with the plates harvested for immunoblotting. Equal transfer of the RNA was evaluated by exposing the gel and later the blot under short-wavelength ultraviolet light to see the intact ethidium bromide-bound 28S and 18S RNA subunits. Note that the EGFr and ErbB2 mRNA expression do not precisely correlate with each other or with their respective protein levels.

 
Figure 3B shows a Northern blot analysis of EGFr and ErbB2 mRNA in cultured hepatocytes. We have previously demonstrated that the increase in ErbB3 protein expression in vitro is associated with increased ErbB3 mRNA (4). Figure 3 shows that the major mRNA transcripts for EGFr and ErbB2 had different expression patterns. Consistent with the in situ hybridization and Northern blot results of Radaeva et al. (22), adult rat hepatocytes did not express ErbB2 mRNA, but the message did appear in cultured cells. For cells exposed to insulin or EGF, the initial decrease in EGFr mRNA within the first 24 h was followed by a second increase at 48 and 72 h. This latter increase may be responsible for the small rebound in EGFr protein expression seen with immunoblot (Fig. 2, top). For both EGFr and ErbB2, the patterns of mRNA change did not correlate precisely with the levels of protein expression. For example, cells cultured in Williams' medium E alone sustained their expression of EGFr mRNA in culture, even though protein levels fell (Fig. 2, top). Also, cells cultured without insulin or EGF showed low levels of ErbB2 protein expression, even though the levels of ErbB2 mRNA compared favorably to insulin- or EGF-treated cells, which expressed much higher levels of ErbB2 protein.

EGF and insulin synergistically stimulate ErbB2, cyclin D1, and DNA synthesis. EGF ligands and insulin synergistically stimulate hepatocyte DNA synthesis (15, 27). EGF acts as a partial agonist of the EGFr-compared with TGF-{alpha} (33). To confirm these findings, we examined the effects of different concentrations of EGF or TGF-{alpha} in the presence or absence of insulin on DNA synthesis. As shown in Fig. 4A, both EGF and TGF-{alpha} synergistically stimulated DNA synthesis between 0.1 and 1 nM, but this synergy disappeared at higher EGF concentrations. We also confirmed in insulin-deficient media that TGF-{alpha} stimulates hepatocyte DNA synthesis more effectively than EGF.


Figure 4
View larger version (12K):
[in this window]
[in a new window]
  		Fig. 4. EGF and insulin synergistically stimulate ErbB2, cyclin D1, and DNA synthesis. A: EGF or transforming growth factor (TGF)-{alpha} synergistically stimulate DNA synthesis between 48 and 72 h of culture. DNA synthesis was measured by the incorporation of [3H-methyl]thymidine into DNA between 48 and 72 h of culture. B: EGF and insulin syngergistically stimulate ErbB2. Densitometry was performed on immunoblot bands from hepatocytes at 50 h of culture. C: EGF and insulin synergistically stimulate cyclin D1. Densitometry was performed on immunoblot bands from hepatocytes at 50 h of culture. Values in A–C are means with error lines as standard deviations of three individual plates.

 
We then studied whether EGF and insulin synergistically stimulated ErbB2 or cyclin D1 expression. The de novo expression of cyclin D1 occurs shortly after 44 h and is thought to play a key role in DNA synthesis (15). We prepared lysates and immunoblots from cells that had been treated with different concentrations of EGF with or without insulin for 50 h of culture. Figure 4, B and C, shows that in insulin-containing medium both ErbB2 and cyclin D1 increase with increasing concentrations of EGF. Insulin did not augment the effect of higher concentrations of EGF (10 nM, data not shown; see Fig. 2 also). These results show that low concentrations of EGF (<1 nM) and insulin synergize to stimulate ErbB2, cyclin D1, and DNA synthesis.

EGF, but not HRG-beta1, stimulates ErbB2 tyrosine phosphorylation. To evaluate the tyrosine phosphorylation state of ErbB2 and possible intermolecular associations between EGFr and ErbB2, we performed immunoprecipitation experiments. We cultured hepatocytes in the presence of insulin (100 nM) for 72 or 96 h. We then exposed the hepatocytes for 2 min to insulin-free medium containing the EGFr ligand EGF (100 nM) or the ErbB3 ligand HRG-beta1 (100 nM). We evaluated the tyrosine phosphorylation patterns of ErbB2 and EGFr immunoprecipitates and determined whether ErbB2 coassociated with EGFr. Figure 5, top, shows the total ErbB2 and EGFr immunoprecipitated from subdivided lysates from cells treated with either no peptide, EGF, or HRG-beta1. Note that the total amounts of ErbB2 or EGFr immunoprecipitated from the different lysates are similar. Figure 5, middle, shows the phosphotyrosine signal associated with the immunoprecipitated ErbBs in Fig. 5, top. Figure 5, bottom, shows the specific phosphotyrosine signal of an antibody raised against a phosphopeptide derived from ErbB2 (Y1112). EGF, but not HRG-beta1, strongly phosphorylated ErbB2 as well as EGFr and promoted the coassociation of these two ErbBs. There is also some basal phosphorylation of EGFr, which is perhaps related to the known ability of these cells to secrete endogenous TGF-{alpha} (1). The inability of HRG-beta1 to increase ErbB2 tyrosine phosphorylation in either the ErbB2 or EGFr immunoprecipitates argues against the formation of active ErbB2-ErbB3 heterodimers or EGFr-ErbB2-ErbB3 higher ordered oligomers. This is consistent with the absence of HRG-beta1-stimulated total tyrosine phosphorylation after 72 and 96 h, as shown in Fig. 1, which we attribute mainly to the greatly diminished ErbB3 expression at these times.


Figure 5
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 5. EGF increases ErbB2 tyrosine phosphorylation and induces EGFr-ErbB2 coassociation. Primary hepatocytes were grown in the presence of insulin. At 72 or 96 h, the cells were treated with EGF (100 nM) or HRG-beta1 (100 nM) in fresh WE for 2 min at 37°C. The control (C) plates were treated with fresh medium but no peptide. Lysates were subdivided. ErbB2 (left) or EGFr (right) was immunoprecipitated from 800 µg of solubilized protein. Immune complexes were electrophoresed and blotted with the immunoprecipitating antibody (ErbB2, top), a general anti-phosphotyrosine antibody (PY99, middle), or an antibody raised against a phosphopeptide derived from ErbB2 (pErbB2, Y1112, bottom).

 
ErbB2 expression is regulated by factors associated with increased cell proliferation. We next evaluated the ability of various "growth activators" to modulate ErbB2 expression in cultured hepatocytes. In the presence of EGF and insulin, nicotinamide (7.5 mM) delays the onset of DNA synthesis by 10–15 h, increases the magnitude and synchrony of peak DNA synthesis, and releases cells from mitotic arrest (19). Figure 6A shows that nicotinamide, which raises the intracellular NAD+ levels, had two effects: it stabilized high levels of EGFr expression, and it delayed the down- and upregulation of ErbB3 and ErbB2, respectively (compare with Fig. 2). Figure 6 with a greater sampling density highlights the reciprocal expression patterns of ErbB2 and ErbB3.


Figure 6
View larger version (22K):
[in this window]
[in a new window]
  		Fig. 6. Increased ErbB2 expression in conditions associated with enhanced cell proliferation. ErbB2 was analyzed by immunoblot with various hormones or agents associated with increased hepatocyte DNA synthesis. A: ErbB proteins were analyzed at different times in cells cultured in the presence of nicotinamide. Note the inverse expression pattern of ErbB2 and ErbB3. B: effect of two different EGFr ligands on EGFr and ErbB2 expression is compared. Immunoblots were performed on cells lysed at 72 h after culture. C: effect of various growth promoters on ErbB2 expression. Different growth promoters were added alone (–) or in the presence (+) of TGF-{alpha} (7.5 nM). Lysates prepared from cells harvested at 72 h were immunoblotted. Glu, glucagon (10 nM); INS (100 nM); PMA (50 ng/ml); HRG (100 mg/ml); HGF, hepatocyte growth factor (10 ng/ml).

 
TGF-{alpha} stimulates hepatocyte DNA synthesis to a greater extent than EGF because a TGF-{alpha}-EGFr complex recycles to the surface membrane, whereas an EGF-EGFr complex is routed to lysosomes for degradation (17). Figure 6B shows that EGF and TGF-{alpha} differentially regulated EGFr and ErbB2 expression at 72 h of culture. TGF-{alpha} stimulated ErbB2 expression at a lower concentration (0.1 nM, as detected in longer autoradiographic exposures). It also induced more ErbB2 at all concentrations tested. EGF, but not TGF-{alpha}, caused a marked downregulation of EGFr. Finally, we evaluated if HRG-beta1 or PMA stimulated ErbB2 expression. These agents have little endogenous growth stimulatory ability but can potentiate TGF-{alpha}-mediated DNA synthesis (32). Figure 6C shows that neither HRG-beta1 nor PMA alone induced ErbB2; however, both increased the TGF-{alpha} induction of ErbB2, akin to their effects on DNA synthesis.

ErbB2 expression is not a target of inhibitors of hepatocyte DNA synthesis. The ability of growth activators to induce ErbB2 suggested that its expression may be a checkpoint for cell cycle progression, potentially sensitive to cell cycle inhibitors. Thus we examined ErbB2 expression in several models associated with decreased cell proliferation, including increased cell density, DMSO (32), and treatment with TGF-beta1. Increasing the plating cell density inhibited DNA synthesis in response to EGF (Fig. 7B). High plating density increased EGFr levels but did not block ErbB2 expression (Fig. 7A). Figure 7C shows that EGF also induced ErbB2 equally well in the presence or absence of 2% DMSO, even though DMSO markedly suppressed DNA synthesis (data not shown). DMSO, however, did reduce EGFr expression in the same cultures.


Figure 7
View larger version (36K):
[in this window]
[in a new window]
  		Fig. 7. Persistent ErbB2 expression despite growth inhibition. ErbB2 expression was analyzed in the presence of agents or conditions associated with decreased entry into the S phase of the cell cycle. A: effect of cell density on EGFr and ErbB2 expression. Cells were plated at three different densities and then harvested at 24, 48, 72, and 96 h of culture. Lysates were prepared and immunoblotted. B: effect of cell density on DNA synthesis between 48 and 72 h of culture. Data are means from triplicate plates. C: cells were treated with DMSO and then lysed at the indicated times and immunoblotted for either EGFr or ErbB2. D: cells were treated with different concentrations of TGF-beta1 for 72 h and then lysed and immunoblotted for ErbB2. E: effect of polarity on ErbB2 expression. Cells were plated on type I collagen for 24 h and then overlayed with Engelbreth-Holm-Swarm extract to restore polarity and intercellular continuity of the canalicular membranes. Cellular protein was solubilized and then immunoblotted.

 
TGF-beta is a potent inhibitor of hepatocyte proliferation (24, 26). TGF-beta1 had a complex dose-response effect on ErbB2 expression (Fig. 7). Low concentrations stimulated ErbB2 expression at 72 h, but the highest doses inhibited it. The stimulatory effect of TGF-beta1 on ErbB2 levels at low concentrations may relate to its ability to induce IGF-1 expression (34), which we have shown also induces ErbB2 (data not shown). Cells treated with the highest doses of TGF-beta1 were apoptotic and likely unable to synthesize a normally induced protein, such as ErbB2.

ErbB2 expression persists in EHS overlay cultures. Hepatocytes cultured on type I collagen lose their polarity as well as their canalicular network, resulting in cholestasis (20). To determine whether ErbB2 expression was a response to aberrant polarity or to bile salt accumulation, we overlaid the cells with EHS basement membrane after 24 h on type I collagen. Under these conditions, the flattened cells assume a polygonal shape and form an anastomosing network of bile canaliculi (20). Figure 7E shows that ErbB2 expression persisted in the EHS overlay cell cultures. Thus the induction was not secondary to the lack of polarity or to cholestasis. EHS overlay did result in increased expression of EGFr and ErbB3, however.

Effects of ErbB2 blockade. To determine the relative contribution of the EGFr and ErbB2 tyrosine kinases to EGF-induced signal transduction, we tested the effects of two ErbB-selective tyrphostins: AG-1478, an EGFr-selective tyrosine kinase inhibitor, and AG-825, an ErbB2 inhibitor (Table 1). The ErbB2 kinase inhibitor AG-825 has at least 60-fold higher selectivity to ErbB2 (IC50 = 0.35 µmol/l) than to the EGFr (IC50 ≥ 19 µmol/l) in cell-free systems and does not inhibit EGFr tyrosine phosphorylation at the concentration used in cell culture (13). AG-1478 and AG-825 each inhibited DNA synthesis at the dosages used by 50%. When combined, the EGFr and ErbB2 tyrphostins inhibited DNA synthesis by nearly 100%, suggesting that both EGFr and ErbB2 play roles in EGF stimulation of hepatocyte DNA synthesis. This is consistent with our prior finding that the dual kinase EGFr-ErbB2 inhibitor PKI-166 was a surprisingly potent inhibitor of DNA synthesis in primary hepatocytes. Because we did not know that ErbB2 was induced in primary hepatocytes at the time of this original study, we originally assumed that this inhibitory effect was entirely related to EGFr blockade. We have obtained similar findings in experiments using AG-1478 and AG-879, an even more selective ErbB2 selective tyrphostin, which has over a 500-fold selectivity to ErbB2 (IC50 = 1 µmol/l) than to the EGFr (IC50 ≥ 500 µmol/l) in cell-free systems (13). The combination of these two tyrphostins at concentrations as low as 0.3 µM completely blocked TGF-{alpha}-stimulated DNA synthesis (data not shown). These data strengthen the implications shown in Fig. 4 demonstrating that EGFr-ErbB2 heterodimers have a role in regulating hepatocyte proliferation.


View this table:
[in this window]
[in a new window]
  		Table 1. Effects of ErbB-selective tyrosine kinase inhibition on hepatocyte EGF-stimulated DNA synthesis

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
EGFr ligands have marked effects on liver cell proliferation, differentiation, apoptosis, cell signaling, metabolism, and carcinogenesis. Hepatocytes express more than 200,000 EGF binding sites per cell. These were originally assumed to be EGFr monomers or homodimers. Recently, we showed that hepatocytes at different developmental stages can also express ErbB2 and ErbB3, which can interact with EGFr monomers to form kinase-active heterodimers (3–5).

In this study, we showed that hepatocyte adaptation to cell culture results in rapid and substantial changes in the abundance, availability, and use of ErbB proteins for signal transduction. Many laboratories rely on primary cultures of hepatocytes in serum-free medium to study the influence of EGF-like ligands on hepatocyte growth and function. However, there is often variation in experimental design, particularly with respect to the culture medium and the time cells spend in culture before experimentation. Some investigators study freshly isolated cells, either attached or in suspension. Others use cells at variable periods after cell attachment. Investigators who transfect cells to express new or dominant negative genes frequently culture cells for as long as 72 h before performing experiments to ensure sufficient foreign protein expression. Our work documents dramatic changes in ErbB receptor expression as cells adapt to culture. Given these changes, differences in experimental design will generate divergent findings when EGF-mediated signaling events are studied.

Several lines of evidence suggest that cultured hepatocytes respond to EGF differently than their counterparts in vivo, and our results implicate the expression of ErbB2 in vitro for many of these differences. The magnitude of the EGF response in cultured hepatocytes rivals that of regenerating liver following partial hepatectomy (as judged by nuclear bromodeoxyuridine or thymidine labeling). Yet despite immediate-early gene activation during cell isolation (18), DNA synthesis does not begin in cultured hepatocytes until 40 h, peaking between 48 and 72 h (15, 24, 26, 35). In the intact adult animal, however, a 70% hepatectomy or an EGF injection given after a priming stimulus will elicit hepatic DNA synthesis within 12 h, with peak DNA synthesis occurring before 24 h (30, 35, 37).

Studies by Sand and Christoffersen (27) and by Loyer et al. (15) have suggested the existence of a late G1 event that sensitizes cultured adult hepatocytes to EGF and facilitates entry into the S phase. This restriction point occurs at about 44 h of culture. One consequence of this restriction point is that cells cultured in insulin become more responsive to EGF with time in culture. When ligand addition is delayed until after this late G1 event, the DNA synthesis response to exogenous EGF becomes synchronized and amplified. For example, when added between 72 and 96 h of culture as opposed to 0 and 24 h, EGF stimulation of peak DNA synthesis occurs in about half the time and is fourfold greater.

We propose that the EGF-sensitizing event that occurs in late G1 is the induction of ErbB2 by insulin and EGF in vitro. Our work thus far has not suggested that ErbB2 induction is a general mechanism controlling cell proliferation in the adult liver. It is not required for DNA synthesis after partial hepatectomy (5) or in a model of hepatic growth following protein deprivation and amino acid gavage (data not shown). However, microarray experiments have shown that adult hepatocytes revert to an embryonic or neonatal phenotype as they adapt to culture (2). Adult rat hepatocytes can express some fetal/embryonic genes, such as {gamma}-glutamyl transpeptidase, as early as 72 h of culture (31). The reemergence of ErbB2 as a signaling molecule in these cells may be representative of this process. In contrast to adult hepatocytes, fetal hepatocytes, which already express ErbB2, exhibit no synergy between insulin and EGF, and their G1/S transition occurs rapidly, within the first 24 h of exposure to EGF (7, 10) (I. Fabregat, personal communication). Thus we speculated that the growth response of cultured adult hepatocytes to EGF required a fetal/neonatal pattern of ErbB expression, including ErbB2.

We demonstrated that hepatocytes expressed ErbB2 shortly before entering the S phase (Figs. 2–3) and that blocking ErbB2 tyrosine kinase reduced DNA synthesis (Table 1). Even though many stimulators of DNA synthesis strongly induced ErbB2 (Fig. 6), its expression was insufficient for DNA synthesis. In fact, ErbB2 expression persisted in some models associated with a decreased proliferative response to EGF (Fig. 7). Collectively, our data suggest that ErbB2 plays a permissive role in the regulation of cell progression into the S phase. However, its expression neither requires nor mandates S phase entry.

The active receptor unit of the EGF signaling complex in the liver can be either an EGFr homodimer or an EGFr heterodimer with ErbB2 or ErbB3. Therefore, changes in the ErbB expression profile, especially the upregulation of ErbB2, may alter EGF cell signaling (8, 9). In various cell systems, the mitogenic signaling capacity of an EGFr-ErbB2 heterodimer is more potent than that of an EGFr homodimer. In contrast to the latter, the EGFr-ErbB2 heterodimer has a prolonged retention at the plasma membrane (presumably from a decreased ability of the heterodimer to engage c-cbl), resulting in increased mitogenic signaling capacity (21). Indeed, we noted that basal and EGF-stimulated protein tyrosine phosphorylation increased with time in culture (Fig. 1). Interestingly, others have reported that the overall tyrosine kinase activity in ErbB2-expressing hepatocytes of fetal/newborn animals exceeds that in the ErbB2-negative hepatocytes of adult animals (12, 16).

ErbB2 may associate with either EGFr or ErbB3, but we found evidence for the association and phosphorylation of ErbB2 only with EGFr (Fig. 5). Immunoprecipitation of ErbB2 from lysates of EGF-treated cells at 44 h of culture showed increased ErbB2 tyrosine phosphorylation and EGFr coassociation, suggestive of heterodimerization. Cells treated with HRG-beta1, an ErbB3 ligand, showed no ErbB2 phosphorylation, even though the ErbB2-ErbB3 heterodimer is the most potent mitogenic signaling pair among the ErbB receptors. We speculate that the relative excess of EGFr favors the formation of EGFr-ErbB2 dimers, possibly having a dominant negative effect on the assembly of ErbB2-ErbB3 dimers. The complementary actions of ErbB2- and EGFr-selective tyrphostins suggest that full EGF signaling depends on the heteromeric association of both tyrosine kinases. These findings are consistent with our prior work showing that a dual EGFr-ErbB2 kinase inhibitor, PKI-166, fully blocked the mitogenic effects of EGF (29).

We have extended our previous observations to define the nature of the "EGF" signaling system in cultured adult rat hepatocytes. We previously showed that ErbB-receptor expression and signaling options vary with the developmental state of the liver in vivo. We now show that a dramatic and rapid change in ErbB expression patterns and signal transduction options occurs during hepatocyte culture. Our findings suggest caution when making inferences about EGF signaling in the liver based solely on signaling studies in cultured hepatocytes. EGF signaling will change as hepatocytes revert to a more fetal pattern of ErbB expression. This includes the expression of ErbB2, which may be the event that allows insulin to amplify the mitogenic effects of EGF. Finally, the action of insulin to induce ErbB2 expression also suggests that it may be under metabolic control, like its homologs ErbB3 (3) and EGFr (6).


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by a student research stipend from the Vanderbilt Diabetes Center (to E. S. Kwak) and from Deborah German, Vanderbilt University School of Medicine Dean of Students (to L. Zhang) and by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-53804 (to W. E. Russell).


   FOOTNOTES
 

Address for reprint requests and other correspondence: L. A. Scheving, Div. of Pediatric Endocrinology, 1055 MRB4, 2215 Garland Ave., Vanderbilt Univ. Medical Center, Nashville, TN 37232-0710 (e-mail: lawrence.a.scheving{at}vanderbilt.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Block GD, Locker J, Bowen WC, Petersen BE, Katyal S, Strom SC, Riley T, Howard TA, and Michalopoulos GK. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF {alpha} in a chemically defined (HGM) medium. J Cell Biol 132: 1133–1149, 1996.[Abstract/Free Full Text]
  2. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, and Suter L. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared with the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 73: 386–402, 2003.[Abstract/Free Full Text]
  3. Carver RS, Mathew PM, and Russell WE. Hepatic expression of ErbB3 is repressed by insulin in a pathway sensitive to PI-3 kinase inhibitors. Endocrinology 138: 5195–5201, 1997.[Abstract/Free Full Text]
  4. Carver RS, Sliwkowski MX, Sitaric S, and Russell WE. Insulin regulates heregulin binding and ErbB3 expression in rat hepatocytes. J Biol Chem 271: 13491–13496, 1996.[Abstract/Free Full Text]
  5. Carver RS, Stevenson MC, Scheving LA, and Russell WE. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Gastroenterology 123: 2017–2027, 2002.[CrossRef][Web of Science][Medline]
  6. Freidenberg GR, Klein HH, Kladde MP, Cordera R, and Olefsky JM. Regulation of epidermal growth factor receptor number and phosphorylation by fasting in rat liver. J Biol Chem 261: 752–757, 1986.[Abstract/Free Full Text]
  7. Gruppuso PA, Boylan JM, Bienieki TC, and Curran TR Jr. Evidence for a direct hepatotrophic role for insulin in the fetal rat: implications for the impaired hepatic growth seen in fetal growth retardation. Endocrinology 134: 769–775, 1994.[Abstract/Free Full Text]
  8. Hendriks BS, Opresko LK, Wiley HS, and Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res 63: 1130–1137, 2003.[Abstract/Free Full Text]
  9. Hendriks BS, Wiley HS, and Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. Biophys J 85: 2732–2745, 2003.[Medline]
  10. Hoffmann B and Paul D. Basic fibroblast growth factor and transforming growth factor-{alpha} are hepatotrophic mitogens in vitro. J Cell Physiol 142: 149–154, 1990.[CrossRef][Web of Science][Medline]
  11. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd, and Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933–8938, 2003.[Abstract/Free Full Text]
  12. Khamzina L and Borgeat P. Correlation of {alpha}-fetoprotein expression in normal hepatocytes during development with tyrosine phosphorylation and insulin receptor expression. Mol Biol Cell 9: 1093–1105, 1998.[Abstract/Free Full Text]
  13. Levitzki A and Gazit A. Tyrosine kinase inhibition:an approach to drug development. Science 267:1782–1788, 1995.[Abstract/Free Full Text]
  14. Liu ML, Mars WM, Zarnegar R, and Michalopoulos GK. Collagenase pretreatment and the mitogenic effects of hepatocyte growth factor and transforming growth factor-{alpha} in adult rat liver. Hepatology 19: 1521–1527, 1994.[CrossRef][Web of Science][Medline]
  15. Loyer P, Cariou S, Glaise D, Bilodeau M, Baffet G, and Guguen-Guillouzo C. Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1. J Biol Chem 271: 11484–11492, 1996.[Abstract/Free Full Text]
  16. Maher PA. Tissue-dependent regulation of protein tyrosine kinase activity during embryonic development. J Cell Biol 112: 955–963, 1991.[Abstract/Free Full Text]
  17. Marmor MD, Skaria KB, and Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903–913, 2004.[CrossRef][Web of Science][Medline]
  18. McGowan JA, Strain AJ, and Bucher NL. DNA synthesis in primary cultures of adult rat hepatocytes in a defined medium: effects of epidermal growth factor, insulin, glucagon, and cyclic-AMP. J Cell Physiol 108: 353–363, 1981.[CrossRef][Web of Science][Medline]
  19. Mitaka T, Sattler CA, Sattler GL, Sargent LM, and Pitot HC. Multiple cell cycles occur in rat hepatocytes cultured in the presence of nicotinamide and epidermal growth factor. Hepatology 13: 21–30, 1991.[CrossRef][Web of Science]
  20. Musat AI, Sattler CA, Sattler GL, and Pitot HC. Reestablishment of cell polarity of rat hepatocytes in primary culture. Hepatology 18: 198–205, 1993.[CrossRef][Web of Science][Medline]
  21. Muthuswamy SK, Gilman M, and Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19: 6845–6857, 1999.[Abstract/Free Full Text]
  22. Radaeva S, Ferreira-Gonzalez A, and Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29: 1453–1462, 1999.[CrossRef][Web of Science][Medline]
  23. Rana B, Mischoulon D, Xie Y, Bucher NL, and Farmer SR. Cell-extracellular matrix interactions can regulate the switch between growth and differentiation in rat hepatocytes: reciprocal expression of C/EBP {alpha} and immediate-early growth response transcription factors. Mol Cell Biol 14: 5858–5869, 1994.[Abstract/Free Full Text]
  24. Russell WE. Transforming growth factor beta (TGF-beta) inhibits hepatocyte DNA synthesis independently of EGF binding and EGF receptor autophosphorylation. J Cell Physiol 135: 253–261, 1988.[CrossRef][Web of Science][Medline]
  25. Russell WE and Bucher NL. Vasopressin modulates liver regeneration in the Brattleboro rat. Am J Physiol Gastrointest Liver Physiol 245: G321–G324, 1983.[Abstract/Free Full Text]
  26. Russell WE, Coffey RJ Jr, Ouellette AJ, and Moses HL. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci USA 85: 5126–5130, 1988.[Abstract/Free Full Text]
  27. Sand TE and Christoffersen T. Temporal requirement for epidermal growth factor and insulin in the stimulation of hepatocyte DNA synthesis. J Cell Physiol 131: 141–148, 1987.[CrossRef][Web of Science][Medline]
  28. Scheving LA and Jin WH. Circadian regulation of uroguanylin and guanylin in the rat intestine. Am J Physiol Cell Physiol 277: C1177–C1183, 1999.[Abstract/Free Full Text]
  29. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, and Russell WE. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem Biophys Res Commun 290: 197–203, 2002.[CrossRef][Web of Science][Medline]
  30. Scheving LA, Tsai TH, Scheving LE, and Hoke WS. Effect of epidermal growth factor (EGF) on [3H]TdR incorporation into DNA in ad libitum fed and fasted CD2F1 mice. Peptides 8: 347–353, 1987.[CrossRef][Web of Science][Medline]
  31. Sirica AE, Richards W, Tsukada Y, Sattler CA, and Pitot HC. Fetal phenotypic expression by adult rat hepatocytes on collagen gel/nylon meshes. Proc Natl Acad Sci USA 76: 283–287, 1979.[Abstract/Free Full Text]
  32. Staecker JL, Sattler CA, and Pitot HC. Sodium butyrate preserves aspects of the differentiated phenotype of normal adult rat hepatocytes in culture. J Cell Physiol 135: 367–376, 1988.[CrossRef][Web of Science][Medline]
  33. Thoresen GH, Guren TK, Sandnes D, Peak M, Agius L, and Christoffersen T. Response to transforming growth factor {alpha} (TGF{alpha}) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of TGF{alpha} is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis. J Cell Physiol 175: 10–18, 1998.[CrossRef][Web of Science][Medline]
  34. Voci A, Arvigo M, Massajoli M, Garrone S, Bottazzi C, Demori I, and Gallo G. IGF-I production by adult rat hepatocytes is stimulated by transforming growth factor-{alpha} and transforming growth factor-beta1. Eur J Endocrinol 140: 577–582, 1999.[Abstract]
  35. Webber EM, Godowski PJ, and Fausto N. In vivo response of hepatocytes to growth factors requires an initial priming stimulus. Hepatology 19: 489–497, 1994.[CrossRef][Web of Science][Medline]
  36. Wollenberg GK, Harris L, Farber E, and Hayes MA. Inverse relationship between epidermal growth factor induced proliferation and expression of high affinity surface epidermal growth factor receptors in rat hepatocytes. Lab Invest 60: 254–259, 1989.[Web of Science][Medline]
  37. Yeh YC, Scheving LA, Tsai TH, and Scheving LE. Circadian stage-dependent effects of epidermal growth factor on deoxyribonucleic acid synthesis in ten different organs of the adult male mouse. Endocrinology 109: 644–651, 1981.[Abstract/Free Full Text]

Related articles in AJP - GI:

Corrigendum

AJP - GI 2006 291: G751. [Full Text]  



This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. A. Scheving, M. C. Stevenson, X. Zhang, and W. E. Russell
Cultured rat hepatocytes upregulate Akt and ERK in an ErbB-2-dependent manner
Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G322 - G331.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. A. Scheving, R. Buchanan, M. A. Krause, X. Zhang, M. C. Stevenson, and W. E. Russell
Dexamethasone modulates ErbB tyrosine kinase expression and signaling through multiple and redundant mechanisms in cultured rat hepatocytes
Am J Physiol Gastrointest Liver Physiol, September 1, 2007; 293(3): G552 - G559.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A corrigendum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in AJP - GI
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scheving, L. A.
Right arrow Articles by Russell, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scheving, L. A.
Right arrow Articles by Russell, W. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.